Study Detail

DEFINE

Status: Open

Type: Interventional

Funder: not available

Sponsor: not available

CI: not available

IRAS-Number: 282934

CPMS-ID: not available

Approval Date: 11 May 2020

Description:

COVID-19 is a global health emergency with significant mortality and has the potential to devastate regions of the world with poor public health and underdeveloped critical care. The key clinical feature is rapid respiratory failure requiring mechanical ventilation (MV). There are no known treatments for COVID-19. The most vulnerable in society may not survive or be suitable for MV. The pandemic is overwhelming health systems across the globe and has the potential to devastate regions of the world with poor public health and underdeveloped critical care. The anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched and overwhelmed. This study aims to support the re-purposing of promising pharmaceutical assets with prior use in humans through performing rapid experimental medicine feasibility studies in small groups of COVID-19 patients. The results of these studies will support further evaluation in existing national and international trial networks. The key interception is to prevent the lung damage in patients with COVID-19 that leads to respiratory failure. This programme will be comprised of small studies (detailed in the protocol appendices) and will focus on how effective the treatments are, as well as their impact on key inflammatory pathways in the body. This study will deliver an overarching and adaptive trial design/platform to provide urgent experimental medicine to support the further development / deployment of candidate therapies for COVID-19 patients.

Back to listing